T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Civeo
CVEO
$347M
| $6.68M | ﹤0.01% |
+22,238
| New | +$6.65M |
|
|
DNB
1402
DELISTED
Dun & Bradstreet
DNB
| $6.67M | ﹤0.01% |
60,535
| – | – |
|
|
BMS
1403
DELISTED
Bemis
BMS
| $6.66M | ﹤0.01% |
163,784
| – | – |
|
1404
BHP
BHP
$221B
| $6.61M | ﹤0.01% |
114,126
+5,913
| +5% | +$347K |
|
1405
Copart
CPRT
$29.1B
| $6.55M | ﹤0.01% |
1,456,800
| – | – |
|
|
TE
1406
DELISTED
TECO ENERGY INC
TE
| $6.49M | ﹤0.01% |
350,965
+20,000
| +6% | +$352K |
|
1407
Jabil
JBL
$38.2B
| $6.42M | ﹤0.01% |
307,413
+23,500
| +8% | +$437K |
|
|
BLOX
1408
DELISTED
Infoblox Inc
BLOX
| $6.39M | ﹤0.01% |
486,170
+62,570
| +15% | +$1.07M |
|
1409
Urban Outfitters
URBN
$6.65B
| $6.37M | ﹤0.01% |
188,090
-83,605
| -31% | -$2.93M |
|
|
SRT
1410
DELISTED
Startek Inc.
SRT
| $6.37M | ﹤0.01% |
824,530
+7,600
| +0.9% | +$54.1K |
|
|
ETRM
1411
DELISTED
EnteroMedics Inc.
ETRM
| $6.33M | ﹤0.01% |
3,861
-5
| -0.1% | -$9.35K |
|
|
BAC.WS.A
1412
DELISTED
Bank Of America Corporation Ws A
BAC.WS.A
| $6.31M | ﹤0.01% |
914,325
-413,977
| -31% | -$3.04M |
|
|
TWTR
1413
DELISTED
Twitter, Inc.
TWTR
| $6.24M | ﹤0.01% |
152,231
-13,411,873
| -99% | -$508M |
|
|
NAUH
1414
DELISTED
National American University Holdings, Inc.
NAUH
| $6.23M | ﹤0.01% |
2,023,343
+600
| +0% | +$2.04K |
|
|
RDC
1415
DELISTED
Rowan Companies Plc
RDC
| $6.19M | ﹤0.01% |
193,833
| – | – |
|
1416
AutoNation
AN
$6.9B
| $6.12M | ﹤0.01% |
102,501
-2,300
| -2% | -$127K |
|
1417
Exponent
EXPO
$3.2B
| $6.07M | ﹤0.01% |
327,616
+21,600
| +7% | +$386K |
|
1418
Bio-Rad Laboratories Class A
BIO
$9.6B
| $6.07M | ﹤0.01% |
50,690
+2,400
| +5% | +$293K |
|
1419
Emcor
EME
$37.5B
| $6.06M | ﹤0.01% |
136,160
-18,500
| -12% | -$840K |
|
|
WFT
1420
DELISTED
Weatherford International plc
WFT
| $6.05M | ﹤0.01% |
262,980
-26,650
| -9% | -$548K |
|
|
FSYS
1421
DELISTED
FUEL SYSTEMS SOLUTIONS INC COM STK
FSYS
| $6.04M | ﹤0.01% |
542,310
+23,930
| +5% | +$249K |
|
|
PDCO
1422
DELISTED
Patterson Companies, Inc.
PDCO
| $5.99M | ﹤0.01% |
151,670
+6,400
| +4% | +$259K |
|
1423
United Rentals
URI
$71.7B
| $5.97M | ﹤0.01% |
56,984
-5,100
| -8% | -$498K |
|
1424
Reliance Steel & Aluminium
RS
$21.6B
| $5.93M | ﹤0.01% |
80,397
-607
| -0.7% | -$43.6K |
|
|
WY.PRA
1425
DELISTED
WEYERHAEUSER COMP PREF CONV SER A (WA)
WY.PRA
| $5.88M | ﹤0.01% |
101,550
-402,450
| -80% | -$22.5M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.